A longitudinal study of immunologic reactivity in leprosy patients treated with immunotherapy

Int J Lepr Other Mycobact Dis. 1994 Dec;62(4):552-8.

Abstract

More than 150 leprosy patients treated with multidrug therapy (MDT) plus immunotherapy (IMT) with a mixture of heat-killed Mycobacterium leprae plus live BCG were studied in relation to humoral and cell-mediated immune responses. Many previously had received prolonged sulfone monotherapy. Patients received 2 to 10 doses of IMT in a period of 1 to 3 years, depending upon their clinical form of leprosy. The patients were followed up for 5 to 10 years with repeated determinations of antibody levels to phenolic glycolipid-I; lymphoproliferative (LTT) responses to soluble extract of M. leprae, to whole bacilli and to BCG, skin-test responses and bacterial indexes (BIs). After MDT plus IMT there was a statistically significant decrease of antibody levels in the multibacillary (MB) group. The BI decreased proportionally to the ELISA results. LTT increased to M. leprae antigens, especially to soluble extract, in a high percentage of these patients (34% of LL patients positive). Lepromin positivity in MB patients increased from 5% initially positive to 75% at the cut-off during this follow up. These results show substantial early and persistent cell-mediated reactivity to M. leprae in many MB patients treated with MDT-IMT, confirming and expanding previously published data.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibodies, Bacterial / blood
  • Antigens, Bacterial*
  • Bacterial Vaccines / therapeutic use*
  • Combined Modality Therapy
  • Enzyme-Linked Immunosorbent Assay
  • Glycolipids / immunology
  • Humans
  • Hypersensitivity, Delayed
  • Immunoglobulin M / blood
  • Lepromin / immunology
  • Leprostatic Agents / therapeutic use
  • Leprosy / drug therapy
  • Leprosy / immunology*
  • Leprosy / microbiology
  • Leprosy / therapy*
  • Leprosy, Borderline / immunology
  • Leprosy, Borderline / therapy
  • Leprosy, Lepromatous / immunology
  • Leprosy, Lepromatous / therapy
  • Leprosy, Tuberculoid / immunology
  • Leprosy, Tuberculoid / therapy
  • Longitudinal Studies
  • Lymphocyte Activation
  • Mycobacterium bovis / immunology
  • Mycobacterium leprae / immunology*
  • Mycobacterium leprae / isolation & purification

Substances

  • Antibodies, Bacterial
  • Antigens, Bacterial
  • Bacterial Vaccines
  • Glycolipids
  • Immunoglobulin M
  • Leprostatic Agents
  • anti-leprosy vaccine
  • phenolic glycolipid I, Mycobacterium leprae
  • Lepromin